Your browser doesn't support javascript.
loading
Pharmacology, Dosing, and Side Effects of Rifabutin as a Possible Therapy for Antibiotic-Resistant Acinetobacter Infections.
Phillips, Matthew C; Wald-Dickler, Noah; Loomis, Katherine; Luna, Brian M; Spellberg, Brad.
Afiliação
  • Phillips MC; Los Angeles County + University of Southern California Medical Center, Los Angeles, California, USA.
  • Wald-Dickler N; Los Angeles County + University of Southern California Medical Center, Los Angeles, California, USA.
  • Loomis K; Division of Infectious Diseases, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
  • Luna BM; Los Angeles County + University of Southern California Medical Center, Los Angeles, California, USA.
  • Spellberg B; Department of Molecular Microbiology and Immunology, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
Open Forum Infect Dis ; 7(11): ofaa460, 2020 Nov.
Article em En | MEDLINE | ID: mdl-33204754
Acinetobacter baumannii has among the highest rates of antibiotic resistance encountered in hospitals. New therapies are critically needed. We found that rifabutin has previously unrecognized hyperactivity against most strains of A. baumannii. Here we review the pharmacology and adverse effects of rifabutin to inform potential oral dosing strategies in patients with A. baumannii infections. Rifabutin demonstrates dose-dependent increases in blood levels up to 900 mg per day, but plateaus thereafter. Furthermore, rifabutin induces its own metabolism after prolonged dosing, lowering its blood levels. Pending future development of an intravenous formulation, a rifabutin oral dose of 900-1200 mg per day for 1 week is a rational choice for adjunctive therapy of A. baumannii infections. This dosage maximizes AUC24 to drive efficacy while simultaneously minimizing toxicity. Randomized controlled trials will be needed to definitively establish the safety and efficacy of rifabutin to treat A. baumannii infections.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Ano de publicação: 2020 Tipo de documento: Article